Single-center experience with the combination of Cardioplexol™ cardioplegia and MiECC for isolated coronary artery bypass graft procedures.

Tevaearai Stahel, Hendrik; Barandun, Silvio; Kaufmann, Emilie; Gahl, Brigitta; Englberger, Lars; Jenni, Hansjoerg; Weber, Alberto; Aymard, Thierry; Gygax, Erich; Carrel, Thierry (2019). Single-center experience with the combination of Cardioplexol™ cardioplegia and MiECC for isolated coronary artery bypass graft procedures. Journal of thoracic disease, 11(Suppl 10), S1471-S1479. Pioneer Bioscience Publishing 10.21037/jtd.2019.04.47

[img]
Preview
Text
Single-center experience with the combination of Cardioplexol™ cardioplegia and MiECC for isolated coronary artery bypass graft procedures.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (250kB) | Preview

Background Cardioplexol™ with its low volume (100 mL) was originally conceived as cardioplegic solution for MiECC procedures. Introduced in its current form in 2008 in our clinic, it has immediately demonstrated attractive advantages including the easy and rapid administration by the surgeon him/herself, the almost immediate cardiac arrest and a prolonged delay before a second dose is necessary. We report here the results of our initial experience with this simple solution. Methods Single centre, retrospective observational analysis of prospectively collected data of isolated coronary artery bypass graft (CABG) procedures performed with a MiECC. Results Of 7,447 adult cardiac surgical operations performed during a 76 months period, 2,416 were isolated CABG-MiECC procedures. Patients were 81.3% males, 66.2±9.7 years old and had a median logistic EuroSCORE of 3.2. In average 3.2±0.8 vessels were bypassed. Median cross-clamp time was 45 minutes and more than 75% of the patients received only one 100 mL dose of Cardioplexol™. At reperfusion more than 90% of the hearts spontaneously recovered a rhythmic activity. Maximal value of troponin T during the first hours following myocardial reperfusion was 0.9±4.5 ng/mL (median =0.4 ng/mL). Mortality at 30 days was 0.9%. Conclusions Cardioplexol™ seems very promising. It appears especially efficient and safe when used for CABG procedures performed with a MiECC.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiovascular Surgery
04 Faculty of Medicine > Pre-clinic Human Medicine > CTU Bern

UniBE Contributor:

Tevaearai, Hendrik; Gahl, Brigitta; Englberger, Lars; Jenni, Hansjoerg; Weber, Alberto; Aymard, Thierry; Gygax, Erich and Carrel, Thierry

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2072-1439

Publisher:

Pioneer Bioscience Publishing

Language:

English

Submitter:

Claudia Stalder

Date Deposited:

18 Jul 2019 11:38

Last Modified:

22 Oct 2019 18:34

Publisher DOI:

10.21037/jtd.2019.04.47

PubMed ID:

31293796

Uncontrolled Keywords:

Cardiac surgery cardioplegia coronary artery bypass graft (CABG) myocardial protection

BORIS DOI:

10.7892/boris.131993

URI:

https://boris.unibe.ch/id/eprint/131993

Actions (login required)

Edit item Edit item
Provide Feedback